Cargando…

Serum proteomic profiling in patients with advanced Schistosoma japonicum-induced hepatic fibrosis

BACKGROUND: Schistosoma japonicum is a parasitic flatworm that is the aetiological agent of human schistosomiasis, an important cause of hepatic fibrosis. Schistosomiasis-induced hepatic fibrosis is a consequence of the highly fibrogenic nature of egg-induced granulomatous lesions, which are the mai...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jing, Yin, Xinguang, Zhang, Lifang, Yao, Ming, Wei, Dahai, Wu, Yiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088642/
https://www.ncbi.nlm.nih.gov/pubmed/33933138
http://dx.doi.org/10.1186/s13071-021-04734-1
_version_ 1783686883674423296
author Huang, Jing
Yin, Xinguang
Zhang, Lifang
Yao, Ming
Wei, Dahai
Wu, Yiming
author_facet Huang, Jing
Yin, Xinguang
Zhang, Lifang
Yao, Ming
Wei, Dahai
Wu, Yiming
author_sort Huang, Jing
collection PubMed
description BACKGROUND: Schistosoma japonicum is a parasitic flatworm that is the aetiological agent of human schistosomiasis, an important cause of hepatic fibrosis. Schistosomiasis-induced hepatic fibrosis is a consequence of the highly fibrogenic nature of egg-induced granulomatous lesions, which are the main pathogenic features of schistosomiasis. Although global awareness of the association between schistosomiasis-induced hepatic fibrosis and S. japonicum infection is increasing, little is known about the molecular differences associated with rapid progression to schistosomiasis in cirrhotic patients. METHODS: We systematically used data-independent acquisition (DIA)-based liquid chromatography-mass spectrometry to identify differentially expressed proteins in serum samples from patients with advanced S. japonicum-induced hepatic fibrosis. RESULTS: Our analysis identified 1144 proteins, among which 66 were differentially expressed between the healthy control group and the group of patients with advanced S. japonicum-induced hepatic fibrosis stage F2 (SHF-F2) and 214 were differentially expressed between the SHF-F2 and SHF-F4 groups (up- or downregulation of at least 1.5-fold in serum samples). The results also indicated that two selected proteins (C1QA and CFD) are potential biomarkers for distinguishing between patients with SHF-F2 and those with SHF-F4 due to S. japonicum infection. CONCLUSIONS: We provide here the first global proteomic profile of serum samples from patients with advanced S. japonicum-induced hepatic fibrosis. The proteins C1QA and CFD are potential diagnostic markers for patients with SHF-F2 and SHF-F4 due to S. japonicum infection, although further large-scale studies are needed. Our DIA-based quantitative proteomic analysis revealed molecular differences among individuals at different stages of advanced S. japonicum-induced hepatic fibrosis and may provide fundamental information for further detailed investigations. GRAPHIC ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13071-021-04734-1.
format Online
Article
Text
id pubmed-8088642
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80886422021-05-03 Serum proteomic profiling in patients with advanced Schistosoma japonicum-induced hepatic fibrosis Huang, Jing Yin, Xinguang Zhang, Lifang Yao, Ming Wei, Dahai Wu, Yiming Parasit Vectors Research BACKGROUND: Schistosoma japonicum is a parasitic flatworm that is the aetiological agent of human schistosomiasis, an important cause of hepatic fibrosis. Schistosomiasis-induced hepatic fibrosis is a consequence of the highly fibrogenic nature of egg-induced granulomatous lesions, which are the main pathogenic features of schistosomiasis. Although global awareness of the association between schistosomiasis-induced hepatic fibrosis and S. japonicum infection is increasing, little is known about the molecular differences associated with rapid progression to schistosomiasis in cirrhotic patients. METHODS: We systematically used data-independent acquisition (DIA)-based liquid chromatography-mass spectrometry to identify differentially expressed proteins in serum samples from patients with advanced S. japonicum-induced hepatic fibrosis. RESULTS: Our analysis identified 1144 proteins, among which 66 were differentially expressed between the healthy control group and the group of patients with advanced S. japonicum-induced hepatic fibrosis stage F2 (SHF-F2) and 214 were differentially expressed between the SHF-F2 and SHF-F4 groups (up- or downregulation of at least 1.5-fold in serum samples). The results also indicated that two selected proteins (C1QA and CFD) are potential biomarkers for distinguishing between patients with SHF-F2 and those with SHF-F4 due to S. japonicum infection. CONCLUSIONS: We provide here the first global proteomic profile of serum samples from patients with advanced S. japonicum-induced hepatic fibrosis. The proteins C1QA and CFD are potential diagnostic markers for patients with SHF-F2 and SHF-F4 due to S. japonicum infection, although further large-scale studies are needed. Our DIA-based quantitative proteomic analysis revealed molecular differences among individuals at different stages of advanced S. japonicum-induced hepatic fibrosis and may provide fundamental information for further detailed investigations. GRAPHIC ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13071-021-04734-1. BioMed Central 2021-05-01 /pmc/articles/PMC8088642/ /pubmed/33933138 http://dx.doi.org/10.1186/s13071-021-04734-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Huang, Jing
Yin, Xinguang
Zhang, Lifang
Yao, Ming
Wei, Dahai
Wu, Yiming
Serum proteomic profiling in patients with advanced Schistosoma japonicum-induced hepatic fibrosis
title Serum proteomic profiling in patients with advanced Schistosoma japonicum-induced hepatic fibrosis
title_full Serum proteomic profiling in patients with advanced Schistosoma japonicum-induced hepatic fibrosis
title_fullStr Serum proteomic profiling in patients with advanced Schistosoma japonicum-induced hepatic fibrosis
title_full_unstemmed Serum proteomic profiling in patients with advanced Schistosoma japonicum-induced hepatic fibrosis
title_short Serum proteomic profiling in patients with advanced Schistosoma japonicum-induced hepatic fibrosis
title_sort serum proteomic profiling in patients with advanced schistosoma japonicum-induced hepatic fibrosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088642/
https://www.ncbi.nlm.nih.gov/pubmed/33933138
http://dx.doi.org/10.1186/s13071-021-04734-1
work_keys_str_mv AT huangjing serumproteomicprofilinginpatientswithadvancedschistosomajaponicuminducedhepaticfibrosis
AT yinxinguang serumproteomicprofilinginpatientswithadvancedschistosomajaponicuminducedhepaticfibrosis
AT zhanglifang serumproteomicprofilinginpatientswithadvancedschistosomajaponicuminducedhepaticfibrosis
AT yaoming serumproteomicprofilinginpatientswithadvancedschistosomajaponicuminducedhepaticfibrosis
AT weidahai serumproteomicprofilinginpatientswithadvancedschistosomajaponicuminducedhepaticfibrosis
AT wuyiming serumproteomicprofilinginpatientswithadvancedschistosomajaponicuminducedhepaticfibrosis